Skip to main content
NIH
Forecasted

FOR-CA-25-090

Forecast to Publish a Notice of Funding Opportunity for The Experimental Therapeutics Clinical Trials Network (ETCTN) Pharmacokinetic Resource Laboratory (U24 Clinical Trial Not Allowed)

Summary

AI-generated

Pharmacokinetics Resource Laboratory for NCI's Experimental Therapeutics Clinical Trials Network

Research Focus

The National Cancer Institute seeks to establish or maintain a Pharmacokinetics Resource Laboratory (PK Laboratory) that will serve as a centralized hub for pharmacokinetic and pharmacodynamic analyses supporting the Experimental Therapeutics Clinical Trials Network (ETCTN). The laboratory will organize biospecimen collections and conduct comprehensive analyses of pharmacokinetic endpoints, drug-drug interactions, cytochrome P450 (CYP) interactions, pharmacodynamics, and food effects in early-phase clinical trials of NCI Investigational New Drug (IND) agents. The core objective is to advance clinical development of cancer therapeutics by providing detailed understanding of how investigational agents behave pharmacokinetically in human subjects. This resource will support translational research and early drug development by engaging multidisciplinary teams including physicians, clinical pharmacologists, nurses, and scientists with expertise in pharmacokinetic studies.

At a Glance

  • Who can apply: Multidisciplinary institutions/organizations with standing infrastructure to support pharmacokinetic studies from trial initiation through clinical development; applications must include three functional cores (Technical Services, Scientific Leadership and Project Development, and Biospecimen Collection/Tracking/Processing/Data Reporting).

  • Funding & project length: Not stated.

  • Award mechanism: U24 (resource/infrastructure grant).

  • Key dates: NOFO expected Summer 2025; application due date anticipated Fall 2025.

  • Best fit for: Academic medical centers and research institutions with clinical pharmacology, bioanalytical chemistry, and biospecimen management capabilities supporting oncology drug development.

Key Facts

Deadline

Posted

Fri, June 27, 2025

Expected Awards

1

Research Areas

NIH Institute
National Cancer InstituteNCI

AI-generated content — verify with the issuing agency’s official FOA/NOFO. Not endorsed by HHS.

© 2026 Biostochastics, Seattle WA · Contact · Terms · About